Accessibility Menu
Abeona Therapeutics logo

Abeona Therapeutics

(NASDAQ) ABEO

Current Price$5.62
Market Cap$316.89M
Since IPO (1996)-100%
5 Year-87%
1 Year-5%
1 Month-1%

Abeona Therapeutics Financials at a Glance

Market Cap

$316.89M

Revenue (TTM)

$14.54M

Net Income (TTM)

$66.14M

EPS (TTM)

$0.94

P/E Ratio

5.93

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$5.62

Volume

2,925,001.324

Open

$5.56

Previous Close

$5.61

Daily Range

$5.53 - $5.72

52-Week Range

$4.00 - $7.54

Estimated Earnings Date

Aug 13, 2026

ABEO: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abeona Therapeutics

Industry

Biotechnology

Employees

226

CEO

Vishwas Seshadri, PhD, MBA

Headquarters

Cleveland, NY 10019, US

ABEO Financials

Key Financial Metrics (TTM)

Gross Margin

51.93%

Operating Margin

-637.92%

Net Income Margin

454.86%

Return on Equity

41.40%

Return on Capital

-48.56%

Return on Assets

33.32%

Earnings Yield

16.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$316.89M

Shares Outstanding

57.00M

Volume

2.93M

Avg. Volume

1.08M

Financials (TTM)

Gross Profit

$7.55M

Operating Income

-$92.75M

EBITDA

$73.43M

Operating Cash Flow

-$77.73M

Capital Expenditure

-$7.51M

Free Cash Flow

-$85.24M

Cash & ST Invst.

$168.27M

Total Debt

$23.17M

Abeona Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.72M

N/A

Gross Profit

$5.16M

N/A

Gross Margin

59.12%

N/A

Market Cap

$316.89M

N/A

Market Cap/Employee

$2.33M

N/A

Employees

136

N/A

Net Income

-$17.08M

-41.9%

EBITDA

-$15.37M

-50.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$168.27M

+100.0%

Total Debt

$23.17M

-3.4%

Accounts Receivable

$6.71M

+314.9%

Inventory

$6.05M

N/A

Long Term Debt

$8.57M

-43.7%

Short Term Debt

$14.61M

+66.7%

Return on Assets

33.32%

N/A

Return on Invested Capital

-55.39%

N/A

Free Cash Flow

-$20.74M

-4.7%

Operating Cash Flow

-$19.80M

-7.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FHTXFoghorn Therapeutics Inc.
$4.22+4.71%
SGMTSagimet Biosciences Inc.
$7.06+2.92%
ELDNEledon Pharmaceuticals, Inc.
$3.78+3.56%
PBYIPuma Biotechnology, Inc.
$8.11+5.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.87+0.02%
SPCXSpace Exploration Technologies
$153.23+0.00%
ONDSOndas
$7.83+0.02%
KEELKeel Infrastructure
$6.03+0.03%

Questions About ABEO

What is the current price of Abeona Therapeutics?

Abeona Therapeutics is trading at $5.61 per share.

What is the 52-week range for Abeona Therapeutics?

Over the past 52 weeks, Abeona Therapeutics has traded between $4.00 and $7.54.

How much debt does Abeona Therapeutics have?

As of the most recent reporting period, Abeona Therapeutics reported total debt of $23.17M.

How much cash does Abeona Therapeutics have on hand?

Abeona Therapeutics reported $61.37M in cash and cash equivalents in its most recent financial results.

What is Abeona Therapeutics’s dividend yield?

Abeona Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.